Comprehensive proteome profiling of molecular endotypes in Japanese adults with moderate-to-severe atopic dermatitis
This study characterizes the circulating proteome and clinical characteristics across putative molecular endotypes in AD. The findings corroborate current knowledge on AD pathophysiology and suggest other axes of dysregulation in a subset of patients with AD. These results may support the development of personalized therapeutic approaches.
Authors
- Robert J. Benschop (ORCID: https://orcid.org/0000-0001-6313-5218)
- Akichika Ozeki (ORCID: https://orcid.org/0000-0001-5510-4219)
- Jonathan T. Sims (ORCID: https://orcid.org/0000-0001-8599-2157)
- Hitoe Torisu‐Itakura (ORCID: https://orcid.org/0000-0002-3200-2882)
- Christoph Preuß (ORCID: https://orcid.org/0000-0003-1039-6080)
- Victoria Serelli-Lee (ORCID: https://orcid.org/0000-0002-4117-4280)
- Takashi Matsuo (ORCID: https://orcid.org/0000-0003-3805-7224)
Institutions
- Eli Lilly (United States) (US)
- Eli Lilly (Japan) (JP)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-11-20
- DOI
- https://doi.org/10.3389/fmed.2025.1649918
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Eli Lilly Japan